Increased risk of ovarian cancer in integrin β3 Leu33Pro homozygotes

Endocrine-Related Cancer

Volumn 12, Issue 4, 2005, Pages 945-952

  Bojesen, S E ^a   Kjaer S K ^b   Hogdall E V S ^b   Thomsen, B L ^b   Hogdall C K ^c   Blaakaer J ^b   Tybjaerg Hansen A ^c,d   Nordestgaard, B G ^a,d  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

^c Rigshospitalet   (Denmark)

^d BISPEBJERG HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BETA3 INTEGRIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER RISK; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE MUTATION; GENOTYPE; HETEROZYGOTE DETECTION; HOMOZYGOTE; HUMAN; HYPOTHESIS; MAJOR CLINICAL STUDY; OVARY CANCER; POPULATION RESEARCH; STATISTICAL ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SUBSTITUTION; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HOMOZYGOTE; HUMANS; INTEGRIN BETA3; LEUCINE; MIDDLE AGED; ODDS RATIO; OVARIAN NEOPLASMS; PROLINE; RISK FACTORS;

EID: 29144479608     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.1.01083     Document Type: Article

References (45)

1. Agorastos T, Masouridou S, Lambropoulos AF, Chrisafi S, Miliaras D, Pantazis K, Constantinides TC, Kotsis A & Bontis I 2004 P53 codon 72 polymorphism and correlation with ovarian and endometrial cancer in Greek women. European Journal of Cancer Prevention 13 277-280.
2. Agoulnik IU, Tong XW, Fischer DC, Korner K, Atkinson NE, Edwards DP, Headon DR, Weigel NL & Kieback DG 2004 A germline variation in the progesterone receptor gene increases transcriptional activity and may modify ovarian cancer risk. Journal of Clinical Endocrinology and Metabolism 89 6340-6347.
3. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Sabate M, Fernandez C, Stranieri C, Trabetti E, Pignatti PF & Macaya C 2004 PlA polymorphism and platelet reactivity following clopidogrel loading dose in patients undergoing coronary stent implantation. Blood Coagulation and Fibrinolysis 15 89-93.
4. A2 alloantigen on the function of beta 3 integrins in platelets. Blood 97 3093-3099.
5. Bojesen SE, Tybjærg-Hansen A & Nordestgaard BG 2003 Integrin beta 3 Leu33Pro homozygosity and risk of cancer. Journal of the National Cancer Institute 95 1150-1157.
6. Bojesen SE, Tybjaerg-Hansen A & Nordestgaard BG 2005 Re: Integrin beta3 Leu33Pro homozygosity and risk of cancer. Journal of the National Cancer Institute 97 779-780.
7. Boncler MA, Golanski J, Paczuski R & Watala C 2002 Polymorphisms of glycoprotein Ib affect the inhibition by aurintricarboxylic acid of the von Willebrand factor dependent platelet aggregation. Journal of Molecular Medicine 80 796-801.
8. Brakora KA, Lee H, Yusuf R, Sullivan L, Harris A, Colella T & Seiden MV 2004 Utility of osteopontin as a biomarker in recurrent epithelial ovarian cancer. Gynecologic Oncology 93 361-365.
9. Bray F, Sankila R, Ferlay J & Parkin DM 2002 Estimates of cancer incidence and mortality in Europe in 1995. European Journal of Cancer 38 99-166.
10. Bridges JE, Englefield P, Boyd IE, Roche WR & Thomas EJ 1995 Expression of integrin adhesion molecules in normal ovary and epithelial ovarian tumors. International Journal of Gynecological Cancer 5 187-192.
11. Cannistra SA, Ottensmeier C, Niloff J, Orta B & DiCarlo J 1995 Expression and function of beta 1 and alpha v beta 3 integrins in ovarian cancer. Gynecologic Oncology 58 216-225.
12. Coppola D, Szabo M, Boulware D, Muraca P, Alsarraj M, Chambers AF & Yeatman TJ 2004 Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clinical Cancer Research 10 184-190.
13. Cruet-Hennequart S, Maubant S, Luis J, Gauduchon P, Staedel C & Dedhar S 2003 alpha(v) integrins regulate cell proliferation through integrin-linked kinase (ILK) in ovarian cancer cells. Oncogene 22 1688-1702.
14. A2 and coronary risk: a meta-analysis. Thrombosis and Haemostasis 85 626-633.
15. Dicioccio RA, Song H, Waterfall C, Kimura MT, Nagase H, McGuire V, Høgdall E, Shah MN, Luben RN & Easton DF 2004 STK15 polymorphisms and association with risk of invasive ovarian cancer. Cancer Epidemiology Biomarkers and Prevention 13 1589-1594.
16. A2 polymorphism - the Framingham Offspring Study. Arteriosclerosis Thrombosis and Vascular Biology 19 1142-1147.
17. Ferlay J, Bray F, Pisani P & Parkin DM 2004 GLOBOCAN 2002 Cancer incidence, mortality and prevalence worldwide. IARC CancerBase No.5. version 2.0 2004, www-depdb.iarc.fr/globocan/GLOBOframe.htm.
18. Gayther SA, Russell P, Harrington P, Antoniou AC, Easton DF & Ponder BA 1999 The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for other ovarian cancer-susceptibility genes. American Journal of Human Genetics 65 1021-1029.
19. Gillan L, Matei D, Fishman DA, Gerbin CS, Karlan BY & Chang DD 2002 Periostin secreted by epithelial ovarian carcinoma is a ligand for alpha(V)beta(3) and alpha(V)beta(5) integrins and promotes cell motility. Cancer Research 62 5358-5364.
20. Glud E, Kjaer SK, Thomsen BL, Høgdall C, Christensen L, Høgdall E, Bock JE & Blaakaer J 2004 Hormone therapy and the impact of estrogen intake on the risk of ovarian cancer. Archives of Internal Medicine 164 2253-2259.
21. Hapke S, Kessler H, Luber B, Benge A, Hutzler P, Hofler H, Schmitt M & Reuning U 2003 Ovarian cancer cell proliferation and motility is induced by engagement of integrin alpha(v)beta3/Vitronectin interaction. Biological Chemistry 384 1073-1083.
22. Høgdall EV, Christensen L, Kjær SK, Blaakær J, Bock JE, Glud E, Nørgaard-Pedersen B & Høgdall CK 2003a Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study. Cancer 98 66-73.
23. Høgdall EV, Kjær SK, Glud E, Christensen L, Blaakær J, Vuust J, Bock JE, Nørgaard-Pedersen B & Høgdall CK 2003b Evaluation of a polymorphism in intron 2 of the p53 gene in ovarian cancer patients. From the Danish 'Malova' Ovarian Cancer Study. Anticancer Research 23 3397-3404.
24. Hood JD & Cheresh DA 2002 Role of integrins in cell invasion and migration. Nature Reviews. Cancer 2 91-100.
25. Johnson GL & Lapadat R 2002 Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298 1911-1912.
26. Kim JH, Skates SJ, Uede T, Wong KK, Schorge JO, Feltmate CM, Berkowitz RS, Cramer DW & Mok SC 2002 Osteopontin as a potential diagnostic biomarker for ovarian cancer. Journal of the American Medical Association 287 1671-1679.
27. Levin ML 1953 The occurrence of lung cancer in man. Acta - Unio International Contra Cancrum 9 531-541.
28. Liapis H, Adler LM, Wick MR & Rader JS 1997 Expression of alpha(v)beta3 integrin is less frequent in ovarian epithelial tumors of low malignant potential in contrast to ovarian carcinomas. Human Pathology 28 443-449.
29. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A & Hemminki K 2000 Environmental and heritable factors in the causation of cancer - analyses of cohorts of twins from Sweden, Denmark, and Finland. New England Journal of Medicine 343 78-85.
30. A polymorphisms display different sensitivities to agonists. Circulation 101 1013-1018.
31. Monos DS, Pappas J, Magira EE, Gaughan J, Aplenc R, Sakkas L, Freedman R, Reveille JD & Platsoucas CD 2005 Identification of HLA-DQalpha and -DRbeta residues associated with susceptibility and protection to epithelial ovarian cancer. Human Immunology 66 554-562.
32. Panda D, Kundu GC, Lee BI, Peri A, Fohl D, Chackalaparampil I, Mukherjee BB, Li XD, Mukherjee DC & Seides S 1997 Potential roles of osteopontin and alpha Vbeta 3 integrin in the development of coronary artery restenosis after angioplasty. PNAS 94 9308-9313.
33. Pharoah PD & Ponder BA 2002 The genetics of ovarian cancer. Best Practice and Research. Clinical Obstetrics and Gynaecology 16 449-468.
34. Rangaswami H, Bulbule A & Kundu GC 2004 Nuclear factor-inducing kinase plays a crucial role in osteopontin-induced MAPK/IkappaBalpha kinase-dependent nuclear factor kappaB-mediated promatrix metalloproteinase-9 activation. Journal of Biological Chemistry 279 38921-38935.
35. Sajid M, Vijayan KV, Souza S & Bray PF 2002 PlA polymorphism of integrin beta 3 differentially modulates cellular migration on extracellular matrix proteins. Arteriosclerosis, Thrombosis, and Vascular Biology 22 1984-1989.
36. Schorge JO, Drake RD, Lee H, Skates SJ, Rajanbabu R, Miller DS, Kim JH, Cramer DW, Berkowitz RS & Mok SC 2004 Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer. Clinical Cancer Research 10 3474-3478.
37. Smith GD & Ebrahim S 2004 Mendelian randomization: prospects, potentials, and limitations. International Journal of Epidemiology 33 30-42.
38. STATA/SE for Windows, rel. 8.2. USA: Stata Corporation 2004.
39. Szaniawska B, Trembacz H, Miloszewska J, Lipkowski AW, Misicka A, Ostrowski J & Janik P 2001 Peptide analog of fibronectin that inhibits cell migration and ERK 1/2 activity. Peptides 22 1949-1953.
40. Terry KL, De Vivo I, Titus-Ernstoff L, Shih MC & Cramer DW 2005 Androgen receptor cytosine, adenine, guanine repeats, and haplotypes in relation to ovarian cancer risk. Cancer Research 65 5974-5981.
41. 3 enhances outside-in signaling and adhesive functions. Journal of Clinical Investigation 105 793-802.
42. Vijayan KV, Liu Y, Dong JF & Bray PF 2003 Enhanced activation of mitogen-activated protein kinase and myosin light chain kinase by the Pro33 polymorphism of integrin beta 3. Journal of Biological Chemistry 278 3860-3867.
43. Wang-Gohrke S & Chang-Claude J 2005 Re: Integrin beta3 Leu33Pro homozygosity and risk of cancer. Journal of the National Cancer Institute 97 778-779.
44. Wheeler GL, Braden GA, Bray PF, Marciniak SJ, Mascelli MA & Sane DC 2002 Reduced inhibition by abciximab in platelets with the PlA2 polymorphism. American Heart Journal 143 76-82.
45. Zimrin AB, Gidwitz S, Lord S, Schwartz E, Bennett JS, White GC & Poncz M 1990 The genomic organization of platelet glycoprotein IIIa. Journal of Biological Chemistry 265 8590-8595.